In the past year, we’ve shared the stories of a number of Alberta children seeking Zolgensma — a $2.8 million drug that replaces the dysfunctional gene which causes spinal muscular atrophy Type 1. That life-saving therapy has now been approved by Health Canada. As Morgan Black reports, the news brings renewed hope to families who’ve been tirelessly fundraising to afford the staggering cost.
Global News Hour at 6 Edmonton
Health Canada approves $2.8M Zolgensma treatment for spinal muscular atrophy
More Videos
-
Global News Hour at 6 Edmonton: Saturday, May 4, 2024
-
Edmonton weather forecast: Saturday, May 4, 2024
-
Trying to solve Edmonton’s ‘Pothole Challenge’
-
First responders working together to improve emergency action
-
WNBA game in Canada one part of the rise of women’s sports
-
Edmonton MP on Pension Plan Protections
You are viewing an Accelerated Mobile Webpage.
View Original Article